Nasdaq Gears Up to Report Q3 Earnings: What's in the Cards?

Nasdaq is expected to report Q3 2026 revenue of $1.47 billion, up 11.7% year over year, and EPS of $1.02, up 15.9%; its +0.98% Earnings ESP and $1.03 most accurate estimate point to a potential beat, not a reported result. Organic growth, technology subscriptions and listings may support results, while higher expenses could pressure profitability; anticipated share buybacks may provide an EPS boost. Trading activity was mixed: U.S. equity options volume rose 12.9% to 1.1 billion contracts, while European options and futures volume fell 15.8% to 12.8 million.

Analysis

The key earnings question is conversion, not activity: higher U.S. options volume alongside sharply lower revenue per contract suggests mix, pricing, or rebates may be absorbing the volume benefit. If that pattern persists, investors may over-credit headline volumes and underweight monetization. European options weakness is a separate drag; stronger European cash-equity activity may not offset it on the same economics. For Cboe Global Markets (CBOE), Nasdaq’s data are a competitive read-through, not evidence of share gains or losses; compare Cboe’s own volume and yield disclosures before inferring relative positioning.

Near term, the Oct. 22 report can move NDAQ on revenue quality and expense control more than on a small EPS beat. Buybacks support per-share results but do not resolve whether recurring revenue growth is outrunning infrastructure, services, and strategic costs. Over 1–3 months, watch subscription renewal/pricing, Financial Crime Management Technology growth, and expense run-rate. Over 6–18 months, durable recurring technology and data revenue could improve earnings quality; the countercase is sustained cost growth and transaction-sensitive activity overwhelming that mix shift. Listing growth is a supportive indicator, but not sufficient evidence of a durable step-up in listing economics. The contrarian point: the upbeat volume narrative may conceal weaker unit monetization, while any beat aided by repurchases may overstate underlying operating leverage.

Key Decisions for Investors

• Avoid a pre-earnings directional NDAQ position based solely on the beat setup. Reassess after the release: require evidence that recurring revenue growth is translating into operating leverage, not just EPS support from repurchases.
• For an existing NDAQ holding, treat U.S. options revenue per contract and European options/futures activity as key risk markers. A further yield decline or weaker outlook alongside rising expenses would falsify the constructive earnings-quality thesis.
• Keep CBOE as a relative-value watch, not an automatic long against NDAQ. Compare reported options volume, revenue per contract, and outlook from both companies; only consider a pair if those data establish a durable monetization or share trend.
• Over the next 1–3 months, monitor subscription growth and expense guidance in Nasdaq’s technology and financial-crime businesses. Strong recurring growth with controlled costs supports the longer-term case; rising costs without matching recurring revenue warrants reducing exposure.